title: [Her2 positive breast cancer: practices].
abstract: The molecular classification of Perou and Sørlie breast tumors has to streamline, systematize and make effective use of targeted therapies against specific molecular subtypes, including breast HER2 positive. Trastuzumab and lapatinib are currently the two therapies targeting HER2, which have demonstrated their effectiveness in clinical practice. This literature review aims to make the data points on pertinent and useful data for physicians in daily.
authors: Institut du cancer Nantes-Atlantiques, centre René-Gauducheau, Saint-Herblain, France. m-campone@nantes.fnclcc.fr
authors: Mario
authors: M
authors: Campone
authors: Dominique
authors: D
authors: Berton-Rigaud
authors: Emmanuelle
authors: E
authors: Bourbouloux
authors: Sadot
authors: S
authors: Sophie
authors: Alain
authors: A
authors: Zanetti
authors: Jean-Sébastien
authors: JS
authors: Frenel